Urothelial bladder cancer progression: lessons learned from the bench

作     者：Julieta P.Afonso Rui Freitas Francisco Lobo António Morais Jorge Oliveira Teresina Amaro Rui M.Reis Fátima M.Baltazar Adhemar Longatto-Filho Lúcio L.Santos 

作者机构：Life and Health Sciences Research Institute(ICVS)School of Health SciencesUniversity of MinhoCampus de Gualtar4710-057 BragaPortugal ICVS/3B’s-PT Government Associate Laboratory4806-909 Braga/GuimarãesPortugal Department of UrologyPortuguese Institute of OncologyRua Dr.António Bernardino de Almeida4200-072 PortoPortugal Experimental Pathology and Therapeutics Research CenterPortuguese Institute of OncologyRua Dr.António Bernardino de Almeida4200-072 PortoPortugal Molecular Oncology Research CenterBarretos Cancer HospitalCEP 14784-400 BarretosSão PauloBrazil Laboratory of Medical Investigation(LIM 14)Faculty of MedicineSão Paulo State UniversityCEP 01246-000São PauloBrazil Department of Surgical OncologyPortuguese Institute of OncologyRua Dr.António Bernardino de Almeida4200-072 PortoPortugal Faculty of Health SciencesUniversity Fernando PessoaRua Carlos da Maia4200-150 PortoPortugal. 

出 版 物：《Journal of Cancer Metastasis and Treatment》 (癌症转移与治疗（英文版）)

年 卷 期：2015年第1卷第1期

页      面：57-66页

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：CD147 lymphovascular invasion mammalian target of rapamycin monocarboxylate transporters progression Raf kinase inhibitor protein scoring system urothelial bladder cancer 

摘      要：Urothelial bladder carcinoma(UBC)is an intricate malignancy with a variable natural history and clinical *** developments in diagnosis/prognosis refi nement and treatment modalities,the recurrence rate is high,and progression from non-muscle to muscle invasive UBC commonly leads to ***,patients with muscle-invasive or extra-vesical disease often fail the standard chemotherapy treatment,and overall survival rates are ***,UBC remains a challenge in the oncology fi eld,representing an ideal candidate for research on biomarkers that could identify patients at increased risk of recurrence,progression,and ***,progress toward personalized medicine has been hampered by the unique genetic complexity of *** genome-wide expression and sequencing studies have brought new insights into its molecular features,pathogenesis and clinical diversity,revealing a landscape where classical pathology is intersected by the novel and heterogeneous molecular ***,it seems plausible to postulate that only an integrated signature of prognostic/predictive biomarkers inherent in different cancer hallmarks will reach clinical *** this review,we have summarized ours and others’research into novel putative biomarkers of progression and chemoresistance that encompass several hallmarks of cancer:tumor neovascularization,invasion and metastasis,and energy metabolism reprogramming of the tumor microenvironment.